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Abstract: Bone Morphogenetic Proteins (BMPs) together with the Growth and Differentiation Factors
(GDFs) form the largest subgroup of the Transforming Growth Factor (TGF)β family and represent
secreted growth factors, which play an essential role in many aspects of cell communication in higher
organisms. As morphogens they exert crucial functions during embryonal development, but are
also involved in tissue homeostasis and regeneration in the adult organism. Their involvement in
maintenance and repair processes of various tissues and organs made these growth factors highly
interesting targets for novel pharmaceutical applications in regenerative medicine. A hallmark of the
TGFβ protein family is that all of the more than 30 growth factors identified to date signal by binding
and hetero-oligomerization of a very limited set of transmembrane serine-threonine kinase receptors,
which can be classified into two subgroups termed type I and type II. Only seven type I and five type
II receptors exist for all 30plus TGFβ members suggesting a pronounced ligand-receptor promiscuity.
Indeed, many TGFβ ligands can bind the same type I or type II receptor and a particular receptor of
either subtype can usually interact with and bind various TGFβ ligands. The possible consequence of
this ligand-receptor promiscuity is further aggravated by the finding that canonical TGFβ signaling
of all family members seemingly results in the activation of just two distinct signaling pathways,
that is either SMAD2/3 or SMAD1/5/8 activation. While this would implicate that different ligands
can assemble seemingly identical receptor complexes that activate just either one of two distinct
pathways, in vitro and in vivo analyses show that the different TGFβ members exert quite distinct
biological functions with high specificity. This discrepancy indicates that our current view of TGFβ
signaling initiation just by hetero-oligomerization of two receptor subtypes and transduction via
two main pathways in an on-off switch manner is too simplified. Hence, the signals generated by
the various TGFβ members are either quantitatively interpreted using the subtle differences in their
receptor-binding properties leading to ligand-specific modulation of the downstream signaling cascade
or additional components participating in the signaling activation complex allow diversification of
the encoded signal in a ligand-dependent manner at all cellular levels. In this review we focus on
signal specification of TGFβ members, particularly of BMPs and GDFs addressing the role of binding
affinities, specificities, and kinetics of individual ligand-receptor interactions for the assembly of
specific receptor complexes with potentially distinct signaling properties.
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1. The SMAD Dilemma: Many Growth Factors but Just Two Principal Signaling Pathways
According to Miyazawa et al.: “TGF-β family ligands trigger signaling through hetero-
oligomerization of two types of transmembrane receptors with intrinsic serine-threonine kinase
activities: the type I and type II receptors. [ . . . ] In the ligand-receptor complex, the constitutively
active type II receptors phosphorylate and activate the type I receptors. The type I receptors
then phosphorylate a subgroup of SMAD proteins, the receptor-regulated SMADs (R-SMADs).
The R-SMADSs comprise SMAD2 and -3 for TGF-β and activin signaling, and SMAD1, -5, and
-8 for BMP signaling. Phosphorylated R-SMADs form a heterotrimeric complex with a distinct
common-partner SMAD (co-SMAD), SMAD4. The complexes then translocate to the nucleus, where
they activate or repress gene expression in association with other transcription factors and transcriptional
coactivators or corepressors (the SMAD signaling pathway)” [1].
Numerous original papers and reviews during the past 20 years have introduced TGFβ/BMP
receptor activation and signaling with these or very similar sentences (e.g., [2–6]). However, comparing
the highly specific in vivo functions of the different TGFβ ligands as identified from animal studies with
such a simple activation mechanism deduced from in vitro experiments or structure studies evidently
raises the issue: How can this array of functions be derived from a receptor assembly mechanism that
leads to subsequent activation of seemingly only two different (canonical) pathways, i.e., either the
SMAD1/5/8- or the SMAD2/3 signaling cascade? (See also Figure 1).
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Figure 1. Usual depiction of the canonical TGFβ signaling pathways. This sketch neglects the presence
of different receptors of either subtype as well as that of heteromeric ligands. Assuming that in this
scenario the individual SMAD proteins of both branches, SMAD 1/5/8 or SMAD 2/3, are activated
similarly, as a consequence a strong signaling convergence must be postulated. This results in a limited
signal specification leading to the central question how these growth factors can then act as morphogens
with highly distinct functions.
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It seems illogical that on the one hand Nature has diversified growth factors of this family to more
than 30 known members, but at the same time restricted the signaling outcome of all ligands to initiate
intracellular signaling pathways in just two different “flavors”. How Nature handles this obvious
discrepancy and might produce ligand-specific signaling outcomes under these conditions, is still a
focus of many research labs worldwide. One possible way out from this dilemma would be that what is
slovenly described as SMAD1/5/8 (or SMAD2/3) signaling, does not constitute a single cascade in which
all three (or the two) R-SMADs, i.e., SMAD1, SMAD5, and SMAD8, qualitatively and quantitatively
deliver an identical signal, which would then invariably lead to identical gene transcription events for
the three (or the two, respectively) SMAD factors. Initial characterization of the TGFβ/BMP pathway
used classical in vitro tools to detect SMAD activation, i.e., antibodies detecting phosphorylation of
conserved serine residues in the C-terminus [7,8] or reporter-gene assays using a minimal promoter
element (e.g., BRE-luc [9] or CAGA-luc [10]). These are however incapable to discriminate between
SMAD1, 5, and 8 (or between SMAD2 and 3) activation and can only specify the particular SMAD
branch. SMAD proteins resemble classical transcription factors that contain a DNA-binding domain,
i.e., the MH1 (Mad homology 1) domain, which is connected via a linker to a transactivation domain,
i.e., the MH2 domain. SMAD1, 2, 3, 5, and 8, representing the R-SMADs, directly interact with type I
receptors and are activated by those through phosphorylation at the C-terminus of their MH2 domain,
i.e., the SSXS motif. They subsequently form heterotrimeric complexes with the shared SMAD4 via
the MH2 domain and the phosphorylated SSXS motif. These complexes then act as transcription
factors to regulate gene transcription. The specificity of the interaction between R-SMADs and type I
receptors determines which R-SMAD branch is activated. R-SMADs 1, 5, and 8 associate with BMP
signaling upon activation by the type I receptors activin receptor like kinase (ALK)1, ALK2, ALK3
and ALK6 and R-SMADs 2 and 3 are linked to activin and TGFβ signaling (as well as some GDFs)
upon activation by the type I receptors ALK4, ALK5, and ALK7. This functional separation is backed
by phylogenetic analyses clustering the R-SMADs into a SMAD1/5/8 and a SMAD2/3 branch [11].
Although SMAD proteins were found to be highly homologous (particularly within their MH1 and
MH2 domains), the three and the two SMAD members within one branch do not share identical amino
acid sequences thereby providing a possibility for a receptor-specific activation. Biochemical analyses,
however, suggested that the specificity of the TGFβ/BMP type I receptor-SMAD interaction might be
solely mediated by a short loop sequence in the receptor (L45 loop) and the R-SMAD protein (L3 loop),
which differs only by a few amino acid residues between the type I receptors activating a different
SMAD branch and two amino acid residues between SMAD1/5/8 and SMAD2/3 [7,12,13]. In addition,
the L45 loop sequences show no amino acid difference between the type I receptors ALK3 and ALK6,
which both activate SMAD1/5/8, or between ALK4, ALK5 and ALK7 known to activate SMAD2/3.
This suggests that these type I receptors might not be able to differentially activate R-SMAD proteins
of one branch [12]. Only the L45 loops of ALK1/ALK2 differ from that of ALK3/ALK6 indicating that
ALK1 and ALK2 might activate R-SMADs of the SMAD1/5/8 branch differently compared to ALK3
and ALK6 [12]. Thus, ALK1/ALK2 might generate a different pattern of activated R-SMADs than
ALK3/ALK6 which might provide the basis for further signal specification.
However, to make matters worse, structural analyses of complexes of SMAD MH1 domains
bound to DNA, i.e., of SMAD1, SMAD2, SMAD3, and SMAD5 showed that the DNA-recognizing
element, i.e., a β-hairpin harboring residues 75 to 82, is identical among all R-SMADs and engages
in identical interactions with DNA [14–16]. While this remarkable finding might insinuate that all
R-SMADs share similar DNA binding properties, one has to keep in mind that R-SMADs are acting
as heterotrimeric complexes and differences in the architecture of these complexes can dramatically
alter DNA recognition and binding. Unfortunately, no structure data are yet available for such
larger full-length R-SMAD/Co-SMAD4 assemblies in complex with DNA making predictions on
a mechanistic scale, how SMAD recognizes DNA to modulate gene transcription, impossible so
far. The phosphorylation of R-SMADs in their C-terminal SSXS motif certainly describes the initial
activation event in canonical TGFβ/BMP signaling, but multiple additional phosphorylation sites
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have been mapped in the DNA-binding MH1 domain and particularly in the linker region of
R-SMADs (for review: [17]). While the sources for these phosphorylations are sometimes unclear
(although involvement of different cytoplasmic kinases has been reported, e.g., cyclin kinases CDK8 and
CDK9 [18]), phosphorylation of these additional sites seems to be ligand-dependent. Furthermore, other
post-translational modifications, e.g., ubiquitylation, SUMOylation, acetylation, and ADP-ribosylation
of R-SMADs have been observed, which can further diversify SMAD signaling (for review: [19,20]).
Since the linker region in R-SMADs is highly variable (even within one SMAD branch), these
modifications might reopen the possibility to encode a receptor-specific phospho-code (or modification
code) to enable a TGFβ/BMP ligand-specific SMAD activation profile despite the limited number of
R-SMADs (see Figure 2). That R-SMADs do indeed have specific functionalities/signals can be seen
from animal studies employing conditional or systemic deletion of the various R-SMADs. Here distinct
phenotypes were observed thereby indicating that R-SMADs of one branch do not necessarily (fully)
compensate for each other, which would be a necessary consequence if all R-SMADs of one branch
signal identically (e.g., [21–27]; for review: [28,29]).
Besides canonical SMAD signaling TGFβ/BMP ligands have also been reported to signal via a
so-called SMAD-independent or non-canonical signaling pathways (for early reviews see. [30,31]).
For instance, TGFβs were shown to activate different MAP kinase pathways, e.g., Erk, JNK and
p38 [32–35], and similar observations were also made for BMP ligands [36–38]. Both, TGFβs and
BMPs were shown to activate the TGFβ-activated kinase 1 (TAK1), which is a MAPKK kinase family
member and is upstream of JNK and p38 [39–41]. Whether MAP kinase activation through TGFβs and
BMPs is indeed fully SMAD-independent is a matter of debate as crosstalk between SMAD and MAP
kinase signaling has been observed (e.g., [42–44]). However, most importantly, while the principal
mechanism leading to canonical (also termed SMAD-dependent) TGFβ/BMP signaling is known,
i.e., ligand binding leads to transphosphorylation in the type I-type II receptor complex leading to
activation of R-SMADs via phosphorylation with subsequent formation of an R-SMAD/Co-SMAD
assembly that translocates to the nucleus, almost nothing is known about the order of molecular events
resulting in non-canonical TGFβ/BMP signaling. Furthermore, whether and how these are addressed
in a ligand-specific manner is not yet understood, although it has been proposed that the nature of the
ligand-binding receptor assembly may play a role [45].
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Figure 2. Specific interaction of particular S AD proteins with transcriptional co-activators. Cytosolic
interaction with other signaling cascades (cross talk) might produce R-SMAD/co-SMAD combinations
interacting highly specific with distinct transcriptional co-activators. This allows the specific translation
of signals induced by an individual TGFβ member thus resulting in a ligand specific regulation of a
particular gene.
2. The Ligand-Receptor Promiscuity Dilemma
While the additional post-translational modifications of R-SMADs described above might
potentially establish a TGFβ/BMP-receptor specific R-SMAD activation code via a so far unknown
mechanism, another observation in TGFβ/BMP receptor activation limits the possibilities for a supposed
direct linkage between a particular TGFβ/BMP ligand and the encoded signal. In publications this
additional dilemma is often stated as:
Weber et al. have stated that: “One important feature of the TGF-β superfamily is the limited
specificity of its ligand-receptor interactions. For more than 30 ligands only seven type I receptors and
five type II receptors are known. Thus, one receptor of a particular subtype has to bind several different
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ligands. But even though the ligands outnumber the available receptors, several BMPs and GDFs have
been shown to interact with several different receptor chains of both type I and type II.” ([46]).
To yield a ligand-specific R-SMAD activation code each of the more than 30 TGFβ/BMP growth
factors would have to address a specific combination of type I and type II receptor chains. Due to
the limited number of receptors—only seven type I and five type II receptors serve the more than 30
ligands—most receptors usually interact with more than one TGFβmember though. In case of the type
I receptors, which relay the ligand-receptor interaction into distinct R-SMAD:Co-SMAD complexes,
this numeral discrepancy indicates that a given TGFβ/BMP member cannot yield a ligand-specific
SMAD activation code if a receptor is utilized by more than one ligand (the limited number of receptors
within this growth factor superfamily was recognized as early as 1992 [47]). To make matters worse,
the above-described inevitable ligand-receptor promiscuity is aggravated by the fact that TGFβ/BMP
members frequently bind to several TGFβ/BMP receptors of either subtype (for reviews: [48–51]).
Hence, various TGFβmembers likely form assemblies with identical receptor composition. This should
inevitably yield identical intracellular signals, if these assemblies do not differ by other properties, e.g.,
architecture, or so far unknown additional components such as e.g., co-receptors. Ligand-receptor
promiscuity was identified by interaction analysis using in vitro methods such as surface plasmon
resonance and utilizing recombinant ligand and receptor proteins (for the latter the extracellular
domains were used) (e.g., [52–54]). These measurements were often verified by cell-based assays,
which analyzed the binding of radioactively labeled ligand proteins to ligand-responsive cell lines or to
cells recombinantly expressing individual receptors [52,55,56]. As a result, out of the 12 type I and type
II receptors serving the more than 30 TGFβ members only two seem to be ligand-specific or at least
limited to a small TGFβ ligand subgroup. The Anti-Mullerian hormone type II receptor (AMHRII)
is so far found to be highly specific for its ligand, Anti-Mullerian hormone (AMH, also known as
Mullerian inhibitory substance MIS), and does not seem to interact with any other TGFβ member [57].
Due to its nature as a type II receptor its impact on SMAD signaling is unclear as SMAD activation is
thought to be solely initiated from the type I receptors recruited into the ligand-receptor assembly.
For AMH utilization of the TGFβ type I receptors ALK2, ALK3 and ALK6 was reported, all of which
are shared with various BMPs, and thus AMH activates SMAD1, 5 and 8 seemingly similar as many
other BMPs [58–60]. Thus, signal specification for AMH might be either due to the tissue-specific
expression of its type II receptor, an AMHRII-specific activation (e.g., phosphorylation code) of the type
I receptors involved or due to non-canonical, SMAD-independent signaling pathways that are initiated
through AMHRII [57]. Besides AMHRII, only another type II receptor, the TGFβ type II receptor TβRII,
shows a similarly high ligand-specificity. However, in contrast to AMHRII that binds a single TGFβ
ligand member, TβRII interacts with all three TGFβ isoforms 1, 2, and 3 although binding strength
considerably varies among the three isoforms [61,62]. Structure analyses of TGFβ ligand-receptor
complexes then provided molecular clues as to why the TGFβ receptor TβRII only interacts with the
three TGFβ isoforms. While TGFβ 1, 2, and 3 share the same ligand architecture with other TGFβ/BMP
members the localization of the receptor binding sites differs (particularly for binding of the type II
receptor TβRII) ([63,64], for review: [49]). In addition, binding of the type I receptor ALK5 to TGFβs
was shown to depend on a direct interaction with TβRII [65]. These two observations might explain
the specificity of the combination of these two TGFβ receptors for TGFβ1, 2, and 3, although earlier
reports identified ALK5 as the potential type I receptor for the SMAD2/3-activating TGFβ member
GDF9 [66]. While the exclusive usage of a TβRII/ALK5 combination by TGFβs indicates that at least
the signal encoded by the sensu-stricto TGFβs might be distinct from other TGFβ members, studies
have shown that TGFβ1, 2, 3 can activate the SMAD1/5/8 pathway in addition to its classical SMAD2/3
activation [67]. Although initial reports suggested alternative TGFβ-receptor assemblies comprising
the SMAD1/5/8-activating type I receptor ALK1 [67,68], recent reports also suggest that TGFβs can
initiate SMAD1/5/8 signaling by heteromeric assemblies comprising both type I receptors ALK2 and
ALK5 [69].
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Given the high ligand-receptor promiscuity it seems therefore imperative to establish: (a) signal
specification-controlling mechanism(s) in order to provide for ligand-specific properties as found
in vivo. In the past 20 years research of numerous groups have identified various different mechanisms
that act either in the cytoplasm or extracellularly, here either located at the cell surface or the extracellular
space (Figure 3). So-called modulator proteins such as noggin, chordin, follistatin or others interfere
with binding of TGFβ ligands to their respective receptors (therefore often also termed antagonists)
(for review: [49,70]). If these modulator proteins exhibit ligand specificities being different to those
of the locally expressed receptors, which serve these TGFβ ligands, these modulator proteins can
indeed specify signals when a mixture of TGFβ growth factors is present. However, as the modulator
proteins are secreted proteins that do not have an intracellular domain capable to directly modulate the
intracellular signaling cascade their effect on the transduced signal is rather indirect by (individually)
altering the local active concentration of individual ligands. At the level of the cell surface, co- or
pseudo-receptors can enable or alter the signaling capabilities of ligands in a subgroup-specific manner
and if these co-receptors harbor a cytoplasmic domain a direct and ligand-dependent modulation of the
transduced signal seems possible (for review: [71]). Also, in the cytoplasm further signal diversification
can be achieved, for instance SMAD signaling can be inhibited or attenuated by inhibitory SMADs,
i.e., SMAD6 and SMAD7. Additional proteins either interacting with the cytoplasmic domains
of the TGFβ/BMP receptors or with R-SMAD proteins can modulate signaling by altering their
phosphorylation status or adding other post-translational modifications (for review [20,72]). However,
new mechanisms other than the current ligand-mediated receptor assembly may be necessary to
explain how these intracellular modifications can discriminate between two different ligands forming
the same assembly (see Figures 2 and 4). As numerous reviews have focused on these types of signal
diversification mechanisms we will not reiterate these aspects in this article. Instead, we would like
to present intrinsic properties of the ligands and receptors of the TGFβ superfamily, e.g., binding
affinities, binding kinetics, formation order and geometry of the ligand-receptor complex as possible
source for signaling diversification. These parameters not only form the basis of the ligand-receptor
interaction, but could also contribute to signal specification as these parameters influence the initial
step of receptor activation and signal transduction.
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Figure 4. Alternative view on SMAD protein activation. This scenario involves the presence of
up to four different receptor chains transmitting more individual signals after binding of homo- or
heterodimeric ligands. If particular SMAD proteins of either branch are phosphorylated differently by
individual type I receptors or type I/type II receptor combinations each ligand might generate specific
combinations of activated SMAD proteins. The different SMAD proteins might now interact specifically
with kinases/phosphatases of other signaling cascades.
3. The Beginning–Correlating Cellular Binding Sites and Receptors
Initial research investigating TGFβ signal transduction was performed using TGFβ ligands that
were recombinantly produced in higher eukaryotic cells [74–77]. Protocols for purification of these
recombinant TGFβ ligand proteins [78–80] as well as their radioactive labeling [52,81] were established,
which was crucial to allow identification of cellular binding sites that could potentially contain the
cognate cell surface receptors the scientific community was searching for. Following this concept and
by using radioactively labeled TGFβ1 (purified from human platelets, [82]) or activin A (derived from
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recombinant expression in CHO cells, [83]), ligand binding sites could be identified on the surfaces of
different cell lines. These sites were not only characterized in terms of binding, but this technique also
provided affinities and could give additionally an estimate about the number of binding sites per cell.
For TGFβ1 Massague and Like reported affinities ranging from about 50 to 90 pM and found about
20,000 binding sites per cell [84]. Similar numbers were published for activin A by Kondo et al. a few
years later [83]. Here, by analyzing different cell lines about 3,500 to 6,500 binding sites per cell were
reported for activin A with affinities ranging from 0.15 to 3 nM [83]. In both studies it was clearly shown
that binding of TGFβ1 or activin A could not be competitively inhibited by any other ligand known at
that time indicating that both TGFβ members interact with a highly specific receptor. Importantly,
Scatchard analyses identified two different types of binding sites for activin A, which exhibited an
approximately ten-fold difference in affinity for activin A and were thus termed “high” and “low”
affinity binding sites. This observation highlights a general problem with this type of experiments as
nothing can be said about the nature of the receptor as to whether it’s a single receptor molecule or
a dimeric or even oligomeric receptor complex with defined architecture and oligomerization state.
Furthermore, additional cell surface structures such as co-receptors or components of the extracellular
matrix (e.g., proteoglycans) could participate in this interaction and thus the affinities and binding
sites determined could represent an unknown structure, which might unfortunately be mistaken as the
cognate receptor. In case of TGFβ1 chemical crosslinking indeed identified three proteins of different
molecular weight contributing to the binding site identified on the cell surface. These were termed type
I, II, and III receptors according to their size. Similarly, the two binding sites with different affinities for
activin A also strongly indicated that either different “receptors” exist or that “receptor subunits” can
form variable receptor assemblies.
Thus, to unravel the nature/architecture found on cells the receptors/receptor components had to
be cloned and produced recombinantly in order to validate their function. The first TGFβ receptors
that were cloned by time-consuming expression cloning approaches were activin type II receptor
(ActRII) in 1991 by Mathews and Vale [85] and TGFβ type II receptor (TβRII) by Lin and co-workers
one year later [61]. Both receptors were identified through screening of cDNA libraries. Subsequently,
ligand binding assays were carried out with transfected cells overexpressing these receptors. Here
binding specificities and affinities found for the interaction of activin A with ActRII recombinantly
expressed on COS cells were identical to those obtained from radio-ligand binding experiments utilizing
non-transfected, activin A-responsive cells. While these observations indicate that the cloned gene
indeed encodes a/the receptor for activin A, several other explanations can be provided to also interpret
these results. Firstly, these data might indicate that only one receptor for activin A exists, which is
capable to transduce the signal into the cell on its own. In this case the stoichiometry of the activin
A:ActRII interaction still remains unknown. Secondly, if a heteromeric receptor is responsible for activin
A signal transduction, the second receptor must be expressed endogenously and no species specificity
barrier must exist preventing the binding of the recombinant (in this case human) activin A protein
to the endogenous receptor (subunit) in COS cells (Chlorocebus aethiops). However, using COS cells
transfected with ActRII and performing chemical cross-linking experiments with radioactively labeled
activin A yielded only a single band in gel electrophoresis while the same experiment performed with
activin A-responsive cells showed an additional band with higher electrophoretic mobility. Considering
the above-described data derived from the related TGFβ system, this observation rendered a potential
mechanism in which ActRII acts as the sole receptor for activin A signaling implausible, despite the
fact that cells transfected with ActRII showed the same affinity for activin A as non-transfected cells
responsive for activin A. As a consequence, the second scenario that suggests a second receptor for
activin A (a so-called type I receptor in analogy to the TGFβ system) best described all observations
available at that time. However, as binding affinities were identical independent of the presence of the
second receptor, either the second receptor does not interact directly with the ligand (which can be
excluded from the observation of a cross-link product in gel electrophoresis) or its interaction with the
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ligand does not (significantly) contribute to the overall binding of the ligand to the receptor comprising
all components.
In the following years modern techniques comprising new cloning strategies and the availability
of luciferase-based reporter gene assays for direct readout of ligand-mediated receptor activation
greatly facilitated the identification of further type I and type II receptors of this superfamily. The newly
identified TGFβ receptors were usually named according to their biological function, e.g., the type I
receptor for TGFβ signaling (TβRI). For type I receptors an alternative naming was established, which
is based on their sequence homology to the original target, the activin type I receptor and hence denotes
type I receptor as activin receptor-like kinases (ALK1 to ALK7) [86]. With these tools, ligand binding
and ligand-mediated function of individual receptors or combinations of type I and type II receptor
pairs could be examined. It is interesting to note that ligand-receptor binding often correlated well with
ligand-mediated receptor activation as measured by reporter gene assays, but there have been reports
in which binding and activity measurements were inconsistent. In such latter cases often binding of a
ligand to a particular TGFβ receptor had been observed, while cell-based assays did not show receptor
activation upon ligand exposure. Sometimes such observations unfortunately led to far-fetched
misinterpretations of the data. For instance, in two early publications identification and functional
characterization of a novel activin type II receptor (ActRIIB) and of two type I receptors were reported,
which are nowadays known as ALK1 and ALK2 (also known as ActRI) [87,88]. Cells transfected with
these type I receptors showed no cross-linking to radiolabeled TGFβ1 or activin A in the absence of the
above-mentioned type II receptors. However, in the presence of activin type II receptors, ALK1 and
ALK2 were cross-linked to radioactively labeled activin A, but not to TGFβ1. Reporter gene analyses
(3TP-Lux; sensitive for SMAD2/3 signaling) revealed that the reporter luciferase was strongly expressed
upon activin A stimulation in cells that were co-transfected with an activin type II receptors and either
ALK1 or ALK2. With current knowledge most of these results must be considered incorrect, as both
type I receptors are known to activate the SMAD1/5/8 pathway but not the SMAD2/3 branch, which
however is the SMAD branch target of activin A. So, either the cell used for the reporter gene analysis
endogenously expressed the correct activin type I receptor (ALK4) leading to the wrong assignment of
ALK1 and ALK2 as activin A receptors or the SMAD reporter used here was too sensitive suggesting
SMAD2/3 activation while in fact SMAD1/5/8 was activated.
Another example in which initial findings led to a premature conclusion was in the identification
of receptors for growth and differentiation factor 5 (GDF5) [89]. Chemical cross-linking experiments
identified the type I receptor ALK6 (also known as BMPRIB) as the exclusive type I receptor to interact
with GDF5. The seemingly exclusive usage of ALK6 as demonstrated by these cell-based assays
was then found to coincide with phenotypes in animal models in which either the gdf5- [90] or the
alk6/bmpr1b [91] gene locus had been deleted. Based on this genotype/phenotype correlation, binding
and functional properties of GDF5 were assumed to be strictly linked to this type I receptor. However,
GDF5 can induce the expression of alkaline phosphatase (ALP) in the pre-chondrocyte cell line ATDC5
and does activate SMAD1/5/8 phosphorylation in the pre-osteoblastic cell line C2C12, although both
cell lines do not express the type I receptor ALK6 [52,92–96]. This clearly indicates that GDF5 can
transduce signals not only via ALK6, but similarly also through ALK3 albeit GDF5′s lower affinity for
ALK3 might result in lower signaling efficiency. This is of importance as the tissue specific expression
of ALK6 seems much more restrained than ALK3 and thus a strict coupling of GDF5 to ALK6 as the
only signaling type I receptor would severely locally restrict GDF5 activity in vivo [89,97–99].
4. Do Type II Receptors Matter for TGFβ/BMP Signal Specification?
The two receptor subtypes exert mechanistically distinct functions during receptor activation:
upon ligand binding at the extracellular side, the type II receptor kinase (which is considered
constitutively active, although autophosphorylation of the type II receptor kinase seems to be required
for full activity (see [17])) first phosphorylates the type I receptor kinase in a type I receptor-specific
membrane-proximal glycine-serine rich domain termed GS-box. This then leads to activation of the type
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I receptor kinase, which subsequently phosphorylates R-SMAD proteins thereby initiating the canonical
signaling cascade (see Figure 1). This sequential activation mechanism with a “non-constitutively
active” type I receptor prior to activation by a type II receptor kinase was considered essential to
enable a strictly ligand-dependent signaling mechanism (e.g., see [100]). In 1996 the Donahoe group
showed that the immunophilin FKBP12 associates with TGFβ type I receptors and keeps them in
an inactivated state [101]. Structural studies on ALK5 and later on ALK2 revealed the molecular
mechanism of this interaction [102,103]. By binding to the GS-box, FKBP12 blocks the type II receptor
kinase from accessing the phosphorylation target sites in the GS-domain and impedes a conformational
opening of the bilobal kinase structure required for its activation. Consistently, mutations found in
ALK2 of patients suffering from the heterotopic ossification disease FOP (Fibrodysplasia ossificans
progressiva) are assumed to destabilize the inactive state leading to a (partially) activated ALK2
receptor kinase [102,104]. However, from the above outlined mechanism type II receptors only seem to
have the task to activate the type I receptor kinase by phosphorylating a few key threonine and serine
residues in the GS-box unique to type I receptors [105,106]. From this perception one could assume
that any type II receptor could do this task as long as it indeed interacts with the given ligand. Thus,
BMPRII as well as ActRII and ActRIIB, which interact with various BMPs/GDFs and activins, might be
utilized promiscuously without affecting downstream signaling. That this assumption is too simple
becomes readily evident from the fact that BMPRII contains a unique ~550 amino acid long cytoplasmic
extension downstream of the intracellular kinase domain [107]. As an alternatively spliced short form,
which ends after the kinase domain, similarly activates canonical SMAD signaling, a modulatory
effect on type I receptor activation, which could alter SMAD signaling, seems unlikely [107,108].
Furthermore, numerous proteins, which were found to interact with the cytoplasmic tail of BMPRII,
all seem to be involved in non-canonical signaling [109]. This might support the idea that BMPRII,
ActRII, and ActRIIB activate a particular type I receptor in identical manner and hence do not influence
canonical SMAD signaling. However, sequence analyses show a higher amino acid sequence variation
in the kinase domains of the type II receptors compared to the type I receptors, which would argue
for a greater variance in enzymatic properties, such as turnover number or substrate affinities and
specificity in the type II receptor kinases. That not all type II receptors necessarily result in similar
receptor activation despite binding the particular ligand was described in a study investigating GDF5
signaling [89]. In the original publication of Nishitoh et al. the strongest expression of the luciferase
reporter gene upon stimulation with GDF5 occurred in cells that were co-transfected with ActRII
and either ALK3 or ALK6 [89]. Lower but still significant luciferase expression was also detected
in cells expressing BMPRII and either one of the above-listed type I receptors, although luciferase
expression was rather weak for the combination BMPRII and ALK3. However more surprisingly, no
GDF5-mediated reporter gene expression was found in cells in which either one of the type I receptors
was co-transfected with ActRIIB, although chemical crosslinking experiments clearly confirmed binding
of GDF5 to this type I-type II receptor combination [89]. The observation made by Nishitoh et al.
presents a curiosity in that a receptor that binds to a TGFβ ligand with an affinity comparable to that for
other receptors of the same subtype did not lead to signaling despite forming a similar ligand-receptor
assembly as other GDF5 type I-type II receptor combinations. A similar observation was made by
Perron and Dodd for BMP7 [110]. In their study of BMP7-evoked chemotaxis of monocytic cells
they could show, that chemotaxis is mediated by the type II receptors ActRII and BMPRII, but not
by ActRIIB [110]. It is important to note here that ActRIIB does not present a per se inactive type
II receptor (that only functions as decoy) since it acts as activating type II receptor for the signaling
of other TGFβ members such as activin A or GDF11 [111,112]. Since GDF11 and activin A activate
SMAD2/3 and GDF5 and BMP7 signal via SMAD1/5/8 the effect of ActRIIB on TGFβ ligand signaling
might be considered SMAD-branch dependent at first sight. However, Perron and Dodd showed
that BMP7-evoked chemotaxis of monocytic cells is due to a non-canonical, SMAD-independent
signaling and thus the different involvement of ActRIIB in TGFβ signaling follows a more complex
mechanism [110]. A similar albeit indirect finding was also made by New and coworkers in a study
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investigating the different biological function of the activin type II receptors ActRII and ActRIIB [113].
Introducing mRNAs encoding for truncated ActRII or ActRIIB receptors (with the kinase domain
deleted and thus acting dominant negative) into Xenopus embryos revealed that the truncated ActRIIB
receptor caused axial defects. In contrast, the truncated ActRII receptors caused the formation of
a secondary axes similar to the phenotype produced by inhibition of BMP4 signaling. Since this
phenotype could not be established by the truncated ActRIIB receptor it indicates, that BMP4 does not
transduce signals via this receptor. Our own experiments investigating type II receptor usage showed
that also BMP2 did not activate SMAD1/5/8 signaling, if ActRIIB was co-transfected with ALK3 in COS
cells, while ActRII and BMPRII in combination with ALK3 were capable to do so (unpublished data,
Weber, D.; Sebald, W. and Nickel J.). This comes as a surprise as in vitro interaction analyses using
surface plasmon resonance (SPR) showed that the extracellular domain of ActRIIB bound BMP2 (and
also GDF5) with the highest apparent binding affinity compared to the other type II receptors although
the differences between the three type II receptors were rather small (about ≤6-fold) [52]. But, what
explanation can be provided that a ligand-receptor assembly consisting of BMP2, ALK3, and ActRIIB
does not form an active signaling complex, while a complex in which ActRIIB is replaced by either
BMPRII or ActRII, both of which share greater than 65% amino acid identity with ActRIIB, do so?
Crystal structure analyses of two ternary complexes of BMP2 bound to ALK3 and ActRIIB (PDB entries
2H62 and 2H64, [46]) and to ALK3 and ActRII (PDB entry 2GOO, [114]) did not reveal any structural
differences in the complex architectures that could explain different receptor activation. It should be
noted that four alternative splice forms (termed B1 to B4) exist for the type II receptor ActRIIB [88].
These splice forms differ by inclusion of a short peptide segment (8 mer) in the extracellular domain
just ahead of the transmembrane helix and/or another peptide insertion (24 mer) in the intracellular
domain also located in close proximity to the transmembrane segment. Splice forms B1 and B2 both
harbor the short segment in the extracellular domain, but differ in the presence or absence of the
intracellular, juxtamembrane segment (B1 contains both insertions, while splice form B2 harbors only
the extracellular insertion and thus closely resembles the type II receptor ActRII). The splice forms B3
and B4 both lack the insertion in the extracellular domain and similarly differ in the presence or absence
of the intracellular splice segment. Radioligand binding of activin A to the four different ActRIIB splice
forms revealed that splice forms B3 and B4 exhibited reduced ligand binding, while splice forms B1
and B2 that both contain the extracellular insertion segment did not show any difference in activin A
binding compared to ActRII (for BMP4 differential binding to these different splice forms could not be
observed, however it must be noted that the overall binding of radioactively labeled BMP4 to ActRIIB
was rather low). This indicates that a removal of a short segment in the extracellular part close to
the transmembrane segment significantly impairs activin ligand binding [88]. While the presence or
absence of the intracellular splice segment did not affect activin A binding nothing is known regarding
whether both splice forms differ in activin A-mediated receptor activation or downstream SMAD
signaling. However, data from an animal model suggest that the ActRIIB B4 splice form, which lacks
both splice insertions, can compensate for the other three splice variants and thus all four forms
possibly present functional type II receptors [115]. In another study Liu et al. could show that in the
osteoblast precursor cell line 2T3 BMP2 can induce SMAD signaling as well as expression of alkaline
phosphatase via ActRIIB [116]. While the splice form of the ActRIIB receptor addressed in this study is
not known, this observation might also point towards cell-type dependent functionality of ActRIIB.
Although it is unclear from these limited data which role the type II receptor ActRIIB takes up in the
signaling of different TGFβ members and by which mechanism these different effects are mediated,
these examples break the simplification of all ligand-interacting type II receptor exerting the same
function and which is often referred to in the following quote: “BMPs signal through two different
types of serine/threonine kinase receptors. Three distinct type II receptors [BMP receptor II (BMPRII),
activin receptor II (ActRII), and ActRIIB] and three type I receptors [BMPRIA, BMPRI1B, and activin
receptor-like kinase 2 (ALK2)] have been identified. The mechanism of receptor activation involves
BMP-induced phosphorylation of two sequentially acting kinases, with the type I receptor acting
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as a substrate for the type II receptor kinase. Activated BMP type I receptors relay the signal to the
cytoplasm by phosphorylating their immediate downstream targets, SMAD1, SMAD5, and SMAD8
proteins.” [117].
Besides the fact that the potentially different functionality of ActRII and ActRIIB can possibly
diversify the signaling outcome for a subset of BMP ligands, utilization of the activin type II receptors
can add further complexity if different TGFβ/BMP ligands are present at the same time. Activin A and
several SMAD2/3-activating GDFs, e.g., GDF1, GDF3, GDF8, GDF10, GDF11, also employ ActRII and
ActRIIB to initiate downstream signaling. However, in contrast to most SMAD1/5/8-activating BMPs,
such as BMP2, BMP4, BMP7, GDF5, etc., the SMAD2/3-activating activins and GDFs bind (in vitro)
both activin type II receptors with considerably higher affinities (see e.g.,: [52,118,119]). Thus, the
activin type II receptors can exert a dual signaling activity in a complex setting in which activin A and
BMP2 (or a similar pair of SMAD2/3- and SMAD1/5/8-activating TGFβ ligands) are simultaneously
present together with either activin type II- and their respective type I receptor. In the absence of
BMPRII, activin A and BMP2 will directly compete for binding to the (shared) activin type II receptor.
Since activin A binds ActRII with much higher affinity compared to BMP2, it will competitively
impede the recruitment of activin type II receptors by BMP2. As a consequence, activin A will act
as a competitive antagonist of BMP2 attenuating BMP signaling independent of the presence of the
activin type I receptor ALK4 required for activin A signaling. A similar antagonism was also reported
between inhibins and BMPs [120]. In the presence of the type I receptor ALK4, subsequent activin A
signaling can provide additional signals (altered gene transcription profile), which dependent on the
cell type can additionally antagonize canonical SMAD signaling induced by BMP2 [121,122]. Hence in
such a setting, the active activin A signaling might attenuate BMP2 signals even more strongly than
would be expected just from pure competition for binding to the shared activin type II receptor ActRII.
Indeed, such antagonistic activities between activin A and BMP2 have been demonstrated in various
biological contexts such as bone development and tumor biology [123,124].
5. BMP Type I Receptor Mysteries–Binding Does Not Mean Receptor Activation
Similar surprises regarding signaling complexity have also been observed for TGFβ/BMP type I
receptors. Cell-based in vitro experiments measuring ligand binding and activation have identified
ALK3 and ALK6 as activating type I receptors of BMP2 and BMP4 [125,126]. This nicely correlates with
observations that both type I receptors bind BMP2 and BMP4 with the highest affinities among all type
I receptors (e.g., [52]). Furthermore, BMP2 (and BMP4, data unpublished) binds the type II receptors
ActRII, ActRIIB, and BMPRII with at least 50- to 60-fold lower affinity than the type I receptor ALK3. In
addition, binding of BMP2 to all type II receptors is characterized by much faster kinetic rate constants
(kon and koff) compared to binding to type I receptors. Based on these pronounced differences it is
assumed that BMP2-mediated receptor activation follows a sequential mechanism, in which the ligand
BMP2 is recruited to the cell surface first by binding to its type I receptor. This intermediate binary
complex then recruits type II receptors leading to receptor activation and subsequent initiation of
downstream intracellular signaling. While GDF5 (as well as GDF6 and GDF7) does exhibit a similar
receptor recruitment order as BMP2, type I receptor usage seems less promiscuous as for BMP2 (type II
receptor interaction and specificity of GDF5 highly resemble that of BMP2 thus the main difference
between BMP2 and GDF5 is the type I receptor specificity, see [52]). In vivo studies have indicated that
the biological functions of GDF5 are coupled to ALK6 [90,91], although in vitro also binding of GDF5
to and SMAD signaling via ALK3 could be confirmed [89,93]. In order to explain this discrepancy,
one might portend that GDF5 binds ALK3 with a 10-fold lower affinity than ALK6, which might not
suffice signaling in vivo. However, in follow-up studies, mutations were identified that remove type
I receptor specificity in GDF5 and GDF5 variants were developed that mimic BMP2 with respect to
receptor binding [93,127]. Most importantly, such a variant, GDF5 R57A, despite binding ALK3 with
identical affinity as BMP2 was still not capable to induce transcription of the same set of genes as
BMP2 (please note type II receptor binding and specificity of GDF5 and this variant highly resemble
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that of BMP2) [127]. Whether this is due to a different SMAD activation profile by BMP2 and GDF5
R57A or a difference in non-canonical signaling of both growth factors is as yet unknown. However,
this finding clearly indicates that different BMP/TGFβ ligands can assemble identical BMP/TGFβ type
I-type II receptor complexes that do not necessarily deliver the same signal. That GDF5 indeed forms a
ligand-receptor complex comprising ALK3 without subsequent receptor activation is confirmed by
the observation that BMP2-mediated expression of alkaline phosphatase was attenuated by GDF5
(as well as GDF5 R57A) in a dose-dependent manner indicating a direct competition mechanism
for the receptor [127]. The mechanistical difference that can lead to this differential activation by
BMP2 and GDF5 is not yet known, but structure analyses did not reveal significant differences in
the ligand-receptor assemblies [127]. Hence a simple mechanism that would involve structurally
different complexes can be ruled out to explain the activation discrepancy. This is also in line with the
observation that the difference between BMP2 and GDF5 in inducing alkaline phosphatase expression
was cell-type specific. It would be very hard to imagine that BMP factors can establish BMP receptor
assemblies with different 3D structures in different cell types.
Receptor activation by BMP6 and BMP7 showed another unexpected twist. Chemical crosslinking
and cell assays identified ALK2 as the most efficient type I receptor for BMP6- and BMP7-mediated
signal transduction [128,129]. Importantly however, both BMPs bind ALK2 in vitro with very low
affinity (see e.g., [52,118,130]), while the two other SMAD1/5/8-activating type I receptors ALK3 and
ALK6 interact with BMP6 and BMP7 with ≥30-fold greater affinities compared to ALK2 [52,130]. It thus
seems odd that ALK2 would be efficiently recruited into a ligand-receptor assembly by BMP6/BMP7
when ALK3 and/or ALK6 are expressed at the cell surface at the same time unless their expression
level is significantly lower. In a situation in which thermodynamic equilibrium would dictate the
composition of the receptor assembly, one would assume that most complexes would harbor one of
the two type I receptors with higher affinity. However, a structure-function study of BMP6 clearly
showed that in the pre-chondrocyte cell line ATDC5 the lower affinity type I receptor ALK2 is required
for induction of alkaline phosphatase expression. This confirms that ALK2 is recruited by BMP6 into a
receptor complex for signaling despite ALK3 being also expressed in ATDC5 cells, which binds in vitro
with 25-fold higher affinity to BMP6 [130]. Since ALK6 is not expressed in this cell line, no conclusion
can be drawn regarding whether BMP6 can alternatively utilize ALK6 for signaling. Analyses of
BMP6′ receptor binding properties showed that N-glycosylation at a site in the type I receptor epitope
of BMP6 is essential for the binding of ALK2. This explains why bacterial-derived BMP6, which does
not carry N-linked glycans, cannot bind ALK2. Since ALK3 and ALK6 do not require N-glycosylation
for interaction, bacterially-derived BMP6 still binds to both type I receptors in vitro, but assembly of
ALK3 containing complexes by BMP6 was found to not result in induction of alkaline phosphatase
expression confirming the necessity of ALK2 for BMP6 signaling. However, when comparing the two
closely related BMPs BMP2 and BMP6, it is not clear why BMP2 can assemble ALK3 into a signaling
BMP type I-type II receptor complex while a similar interaction of ALK3 with bacterially-derived BMP6
does not initiate downstream signaling. While one might argue that BMP6 binds ALK3 much more
weakly than BMP2, which might impede initiation of signaling via ALK3 this kind of argumentation
seems preposterous given the fact that interaction of BMP6 with ALK2 is even weaker. Unpublished
data from the Sebald lab suggests that signaling of BMP6 could be even more complex (see also [131]).
Here, induction of ALP expression by glycosylated BMP6, non-glycosylated BMP6 and BMP2 were
analyzed in the pre-osteoblast cell line C2C12 (these cells express the BMP type I receptors ALK2
and ALK3 but not ALK6; see [100,129]). In this experiment, ALP expression was induced by BMP2
and glycosylated BMP6, but not by non-glycosylated BMP6 confirming the hypothesis that BMP6
signaling requires recruitment of ALK2. Surprisingly however, ALP expression by glycosylated BMP6
could be down-regulated by an ALK3-neutralizing antibody (AbD1556 and AbD1564, see [132]) in a
dose-dependent manner [131]. While for BMP2-mediated ALP expression this would be expected as
BMP2 utilizes ALK3 as is known, the downregulation of BMP6-mediated ALP induction comes as a
surprise as the above-described experiments already identified ALK2 and not ALK3 as signaling type I
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receptor of (glycosylated) BMP6. One explanation for this observation might be that (glycosylated)
BMP6 assembles a heteromeric type I receptor complex in which ALK2 and ALK3 are both required for
signaling. The ligand-dependent formation of ALK2-ALK3 heterodimers has been described recently
to play a role in the regulation of hepcidin (a BMP6 target) in hepatocytes although the molecular
mechanism of this type I receptor heterodimerization remains unclear [133].
Additionally, as consequence of the low affinity of BMP6 (as well as BMP7) for ALK2 it seems
unlikely that these two BMPs are recruited to the cell surface via their interaction with ALK2.
Instead BMP6 and BMP7 are possibly “anchored” to the cell membrane via the interaction with
their type II receptors and these complexes subsequently recruit the type I receptor ALK2 to initiate
signaling. Consequently, receptor assembly order of BMP6 (and BMP7) would be reversed compared
to BMP2/BMP4 and could thus follow the same sequence as observed for activin A and most
SMAD2/3-activating TGFβ ligands. Although it is not clear whether this will alter SMAD signaling
of BMP6/BMP7 in comparison to that of BMP2/4 theoretical considerations suggest that reversal of
receptor recruitment order could potentially influence downstream signaling at least in a quantitative
manner. In the receptor recruitment scheme of BMP2 dissociation from the type I receptor is so slow that
each particular ligand will likely activate only two type I receptors (i.e., due to the dimeric nature of the
BMP ligand) and thus one ligand molecule will basically yield one activation signal. For BMP6/BMP7
(as well as TGFβ ligands which bind type I receptors with low affinity) the activated “low-affinity”
type I receptor might dissociate from the membrane-located BMP-type II receptor complex to be
replaced by another type I receptor, which might then get activated too. Hence, TGFβ ligands with this
type of receptor recruitment order could activate multiple type I receptors per ligand-type II receptor
assembly and thus a signal amplification might be possible for such ligands. Such an amplification
mechanism would nicely explain the extreme sensitivity of some cell lines to TGFβ ligand exposure
with half-maximal effective concentrations (EC50) far (in orders of magnitude) below their receptor
affinities (KD values). For instance, growth of mink lung cells is blocked by the addition of TGFβ2
with EC50 values in the low pM range (0.6 pM ~ 2 pM) [134], whereas SPR measurements revealed
binding affinities for the TGFβ2:TβRII interaction with KD values in the low nM range (5nM) [135].
This different receptor recruitment order might not only exert quantitative effects but could also
lead to qualitative differences in signaling. As the receptors comprise a kinase activity, different lifetimes
of the receptor in the assembly could result in different phosphorylation patterns in the cytoplasmic
domains of the activated receptors dependent on the enzymatic properties, i.e., Michaelis-Menten
constant (“affinity”) and turnover number (conversion rate). A type I receptor that dissociates fast from
the BMP ligand-receptor assembly might not be phosphorylated at all sites compared to a type I receptor
whose dissociation rate is slow. Differences in the receptor recruitment order and ligand-specific
residence times of the individual type I and type II receptors in the ligand-assembled complex might
thus enable a fine-tuning of receptor activation leading to differences in the encoded signals.
6. Heterodimeric Ligands–An Unexplored World
The above-described observations on BMP6 signaling already provided a hint that BMPs might
be principally capable to assemble heteromeric receptor complexes harboring different receptors of
each subtype thereby leading to receptor assemblies that contain two different type I receptor and/or
two different type II receptors. While the homodimeric nature of TGFβ/BMP ligands rather seems to
argue for symmetric receptor assemblies, similar binding affinities of TGFβ/BMP ligands for different
receptors of one subtype, also known as ligand-receptor promiscuity, can however allow for assemblies
consisting of four different receptors of which two belong to subtype I and two belong to subtype II
(see Figure 4). Formation of such asymmetric receptor assemblies might be enforced by heterodimeric
TGFβ/BMP ligands, which contain two distinct epitopes for type I receptor and two distinct sites for
type II receptor interaction. However, experimental evidence for naturally occurring heterodimeric
TGFβ ligands unfortunately is sparse except for the members of the Activin/Inhibin subgroup ([136],
for review [137]). Direct experimental proof on the existence of naturally occurring heteromeric
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BMP ligands has so far been published for fish and fly [138–141]. Studies employing heterodimeric
mammalian BMP ligands were therefore performed with recombinantly produced proteins. Due to the
disulfide-linked dimer architecture that impedes formation of heterodimers outside the producing
cell, the heterodimeric BMPs usually had to be produced by simultaneous co-expression of two BMP
ligand genes (e.g., [142,143]). There is one exception to this rule, i.e., BMP15 and GDF9, which both
lack the cysteine residue involved in intermolecular disulfide formation. Hence BMP15 and GDF9
can form heterodimers from homodimeric BMP15 and GDF9 in the extracellular lumen even when
secreted from different cells [144]. The resulting BMP15:GDF9 heterodimer was found to exert unique
biological functionalities (termed synergistic functions) not present in the homodimeric growth factors
and that might be related to the fact that the heterodimer can simultaneously activate the SMAD2/3
(through its GDF9 subpart) and the SMAD1/5/8 (through its BMP15 subpart) branch [144–147].
A number of studies have investigated also other heterodimeric BMPs, mostly BMP2/6, BMP2/7,
and BMP4/7, which were recombinantly produced and purified from co-expression in eukaryotic cell
culture or from expression in bacteria and subsequent refolding [142,143,148]. A common observation
of these studies was the strongly increased activity of the heterodimeric BMP proteins (i.e., lower
half-maximal effective concentrations required to observe similar transcription levels of marker genes)
compared to their homodimeric paralogues [143,148–153]. Different mechanisms were proposed to
explain how these increased bioactivities might be exerted. One possibility might be the assembly
of asymmetric receptor complexes that harbor different type I and type II receptors as suggested
above (see Figure 4) [154]. For the type II receptor interactions such possible heteromeric assembly
could be directly inferred from the type II receptor specificity of the related homodimers as the
complete type II receptor epitope is formed within one ligand monomer [50]. The situation is however
different for the type I receptors as both ligand monomers contribute to the formation of one type I
receptor binding epitope and thus a novel type I receptor epitope will be created in the heterodimer
not identical to either one of the related homodimeric BMPs [50]. Hence it is not clear how type I
receptor specificity/specificities and affinities will be affected in such BMP heterodimers. Unfortunately,
there are yet no studies published that investigated receptor binding parameters in heterodimeric
BMPs in a quantitative manner. Unpublished data from the Sebald lab however indicated that the
heterodimeric BMP2/6 and BMP2/7 bound ALK3 in a very similar manner as homodimeric BMP2, i.e.,
with high-affinity in the low nanomolar range (see also [131]). Most importantly, the bacterially-derived
(hence non-glycosylated) heterodimeric BMP2/6 did not seem to bind ALK2 and this finding was
thus consistent with the hypothesis that ALK2 binding requires N-glycosylation in BMP6, which
cannot be present in bacterially-derived BMP2/6. Despite the inability of bacterially-derived BMP2/6 to
bind ALK2, the heterodimeric BMP could nevertheless very efficiently induce expression of alkaline
phosphatase (ALP) in cell types that could not be stimulated with bacterially-derived homodimeric
BMP6. This suggests that the enhanced activity of bacterially-derived BMP2/6 is not necessarily a
consequence of simultaneous binding of two different type I receptors as suggested above, but due
to other so far unknown mechanisms. For instance, Little and Mullins proposed that the enhanced
bioactivity of the BMP2/6 heterodimer is due to the simultaneous presence of a high-affinity binding
site for a type I receptor, here ALK3 (derived from the “BMP2 site”), and a high-affinity binding site
for a type II receptor, i.e., ActRIIB (derived from the BMP6 monomer subunit) [154] (which could
be confirmed by in vitro binding analyses [155]). Consistent with this hypothesis, Seeherman et al.
presented a strategy to create “hyperactive” BMPs with maximal bone restoration capacity [156]. Here,
instead of utilizing a BMP heterodimer, the authors designed different activin/BMP chimeras with
tailored type I and type II receptor binding properties. These homodimeric chimeras that comprised
elements of BMP2, BMP6 and activin A showed high affinity binding to all three BMP type I receptors
(ALK2, ALK3 and ALK6) as well as to all three type II receptors, i.e., BMPRII, ActRII and ActRIIB [156].
As anticipated these chimeras exhibited significantly greater bioactivity than the wildtype BMP analogs
in vitro and in vivo and performed on par or even better than the BMP2/6 heterodimer. Although
this observation might indicate that the elevated activities are due to high-affinity binding of both
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receptor subtypes we cannot rule out that this capacity is achieved through the assembly of different
receptors of either subtype since these “artificial” chimeric growth factors were highly promiscuous
and could bind various receptors of either subtype with seemingly identical affinity. It is important to
note that the above-described example of heterodimeric BMP15:GDF9 clearly suggests that asymmetric
assembly of different type I and different type II receptors not only has quantitative effects, e.g., higher
activity than observed for the homodimeric analogs, but can also alter the gene transcription profile
(possible mechanism is depicted in Figures 2 and 4). Hence such asymmetric receptor complexes might
encode unique and distinct functions not observed with symmetric receptor assemblies and thereby
provide for signal diversification on basis of combinatorial receptor usage. Unfortunately, detailed
gene expression analyses to compare the transcriptional profile of heterodimeric ligands with those
from their homodimeric relatives have not yet been done. Importantly, the above-described example
of BMP6 signaling suggests that asymmetric receptor assembly formation is not necessarily limited to
heterodimeric ligands but could also be initiated by homodimeric ligands. Thus, to determine the
“contribution” of each receptor to ligand signaling gene expression analysis should be performed
using a panel of neutralizing antibodies raised against each of the TGFβ/BMP receptors to individually
cancel participation of each receptor in the ligand-receptor assembly.
Finally, one might ask whether in mammals heterodimeric TGFβ/BMP ligands have a real
physiological significance at all as the above-listed examples exclusively report from recombinantly
produced BMPs. However, existence and occurrence of heterodimeric TGFβ/BMP ligands might
be highly underrated due to lack of published data which again might be related to difficulties to
experimentally detect these heterodimeric forms (particularly in the presence of homodimeric BMPs).
Two older publications from the groups of Sampath and Wozney provided experimental proof for the
existence of heterodimeric BMPs in mammals, however, not much further evidence has been added
since then [157,158]. Recently new reports were published confirming the presence and function of
heterodimeric BMP ligands in mammals [159,160]. These articles for the first time also describe novel
and unique functions for such heterodimeric BMPs that cannot be exerted by a single homodimeric
analog or a combination of both wildtype BMPs indicating that formation of heteromeric ligands can
increase the signaling function and diversity of this protein family. This raises the question about the
frequency with which heterodimeric TGFβ/BMP ligands occur and in which possible combinations they
naturally exist. Considering that simple co-expression of two BMP genes was found to be sufficient for
recombinant production it is unclear whether restrictions exist that would allow only heterodimer
biosynthesis of certain combinations of TGFβs/BMPs. One potential mechanism that could facilitate or
impair biosynthesis of certain heterodimers is in the biosynthesis of TGFβ/BMP ligands as precursor
proteins consisting of a large N-terminal prodomain and a smaller C-terminal mature domain that
harbors the activity of the TGFβ/BMP ligand. Upon secretion the prodomain is cleaved by proteolysis
by metalloproteases of the furin family but in certain TGFβ/BMP ligands remains stably associated
in a non-covalent complex with the mature domain to downregulate the bioactivity of the latter in a
process termed latency (for review see [49]). Release of the mature C-terminal growth factor domain
in these cases is then due to an active process regulated for instance by interaction with integrins.
Structure analyses of such TGFβ/BMP proprotein complexes showed that parts of the prodomain of
one monomer subunit fold into and interact with parts of the other monomer ([161–163], in particular
see: [164]). Hence in heterodimeric TGFβ/BMP proprotein complexes such interaction can either
stabilize and thus facilitate heterodimer formation or by destabilizing impair heterodimer folding
and formation.
While it is thus unclear how many different heterodimeric BMP ligands exist and to what extent, it
must be assumed that endogenous heterodimeric TGFβ/BMP ligands play a role in mammals. This has
important consequences as many functions of TGFβs and BMPs on an organismic level were derived
from knockout animal models (see review: [165]) and the phenotypes observed were solely attributed
to a loss of the respective homodimeric ligand protein. However, assuming that knocking out a single
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TGFβ/BMP gene will also result in the loss of (several) heterodimeric TGFβ/BMP ligands certain
functions might have been misaddressed to the homodimeric TGFβ/BMP analogues.
7. Conclusions
Observations and data summarized in this review indicate that our understanding of the molecular
mechanisms of TGFβ/BMP signaling is still rather limited. From introductory descriptions in various
original publications and reviews one might suppose a rather simple activation mechanism for TGFβ
members in which the ligand (usually presumed homodimeric) assembles a symmetrical receptor
complex comprising two type I and two type II TGFβ/BMP receptors of the same kind (as hypothesized
from structure studies) leading to the activation of one of two principal downstream intracellular
signaling cascades, i.e., SMAD1/5/8 or SMAD2/3. In these two principal cascades SMAD1, SMAD5
and SMAD8 (or SMAD2 and SMAD3 for the other group of ligands) are used synonymously and
therefore termed SMAD1/5/8 (or SMAD2/3) potentially implicating that all R-SMADs of each branch
deliver equivalent signals on transcriptional activation level. While this simplistic view somehow
suggests a strongly converging signaling in which the more than 30 ligands through utilizing a too
small set of only 12 receptors feed into just two signaling cascades, the diverse functions found
for the more than 30 TGFβ members in vivo form a clear contrast to this impression (see Figure 1).
The pronounced ligand-receptor promiscuity observed for numerous TGFβ/BMP ligands in vitro
would further aggravate this signaling convergence problem as multiple ligands of the TGFβ family can
form receptor assemblies with identical receptor composition, which should consequently deliver the
same signals and hence encode identical functions, opposite to what is observed. Here we showed that
while a ligand can bind several different receptors of either subtype (even if this occurs with comparable
affinities) not all of these combinations necessarily deliver the expected receptor activation and signal.
Such puzzling observations were made for type I as well as for type II receptors. Combinations of TGFβ
type I and type II receptors that yielded a signal with a particular TGFβ member were found silent if
assembled by a different ligand of the same TGFβ subgroup. That indeed the same receptors were
assembled in these experiments could be reasoned from the fact that ligands could antagonize each
other by competing for receptor binding. Thus (promiscuous) ligand-receptor interaction determined
in vitro should not be mixed with (uniform) receptor activation. Unfortunately, we cannot provide a
proven mechanism explaining for this surprising finding.
One possible mechanism could be different assembly lifetimes that are due to different receptor
affinities of the different ligands. As the receptors function as enzymes (kinases with possibly distinct
enzymatic parameters, i.e., KM and kcat) different receptor complex lifetimes may translate into
distinct phosphorylation patterns either in the receptors themselves and/or in the intracellular (protein)
substrates (one of which are the R-SMADs) thereby leading to different activation states. Similarly,
receptor recruitment order, i.e., which receptor subtype is bound first and remains in complex with
the TGFβ ligand at the cell surface until endocytosis, could influence the activation status/degree of
the receptor as well as that of downstream targets. Thus, a more intelligible concept would be not to
consider TGFβ receptor activation to work like a two-state on/off switch (which is always identically
activated once the complex is assembled), but to look at the slightly different binding properties of
the various ligands as a biologically significant intrinsic property that can be translated into distinct
activation profiles. However, studying such details, e.g., ligand binding affinities or enzymatic
properties of the receptor kinases, has been and still is regarded as nit-picking and thus systematic
investigations have not yet been performed to figure if and how such differences modulate signaling.
In addition, the chemical nature of TGFβ ligands in vivo is unclear. As dimeric proteins, TGFβ
ligands were and still are considered to exist as homodimers (mostly) although recombinant production
highlights the simplicity with which heterodimeric TGFβ/BMP growth factors can be obtained from
expression in eukaryotic cells. It is thus not known which and to what extent heterodimeric TGFβ/BMP
ligands are endogenously produced in the different organisms, but it seems at least reasonable to
assume that such heteromeric growth factor species occur naturally in many species. In the past many
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of the in vivo functions of TGFβ members that were deduced from animal models (transgenic of
knockout) have been associated solely with the homodimeric forms, neglecting the possibility that some
of these functions might originate from heterodimeric ligand species, which were “co-addressed” by
the genetic manipulation. Hence, functionalities that cannot be reproduced by recombinant TGFβ/BMP
proteins in vitro might be due to false assignment and could be a result from a heterodimeric species
instead. While studies using recombinant heterodimeric TGFβ/BMP ligands have revealed strongly
enhanced signaling activities and unique functions the molecular mechanism by which their signaling
differs from that of related homodimeric ligands members is unclear. From the inherent asymmetry of
heterodimeric TGFβ ligands enhanced formation of heterotetrameric receptor assemblies that harbor
two different type I and/or two different type II receptors has been proposed as molecular cause for
enhanced activity and altered signaling. However, whether this is indeed due to different kinase
domains that might exhibit different substrate specificities or due to enhanced binding/stability of
the assembled receptor complex is not known. While asymmetric receptor complex formation seems
certainly more intelligible for heterodimeric TGFβ ligands, the above example of BMP6 signaling
shows that assembling heterotetrameric receptor complexes is not limited to heterodimeric ligands.
Finally, statements that SMAD signaling has two branches, i.e., SMAD 1/5/8 and SMAD 2/3 might
be misconstrued such that all TGFβ members utilizing SMAD 1/5/8 can uniformly activate any of the
three R-SMADs with identical outcome for gene expression (the same would be assumed for SMAD
2/3-activating TGFβ members). However, tools used to analyze SMAD activation, e.g., antibodies
binding to the phosphorylated C-terminus of the SMAD proteins, can only discriminate between the
two branches, i.e., SMAD 1/5/8 or SMAD 2/3, but cannot specify the particular nature of the activated
SMAD (or whether the different SMADs of one branch are differently activated) due to the high
sequence similarity within the phosphorylation motif detected by the antibody. Similarly, analysis of
SMAD signaling through measuring reporter gene expression is done by using an artificial promoter
harboring one or several SMAD-binding elements that cannot discriminate between SMAD 1, 5 and
8 (or between SMAD 2 and 3). Hence, no specification can be deduced as to whether and which
R-SMAD might be preferentially utilized by a particular ligand-receptor assembly on a cell. Similarly,
nothing is known about the gene expression profile of a particular R-SMAD factor. R-SMAD proteins
are multidomain proteins that heterotrimerize together with a Co-SMAD thereby forming the core of
transcriptional regulation. Besides the two highly conserved MH1 and MH2 domains that engage
in similar SMAD-SMAD or SMAD-DNA interactions, all five R-SMADs have a very distinct linker
domain between the MH1 and MH2 domain that is subject to strong post-translational modification,
e.g., phosphorylation by other kinases. In addition, SMAD proteins also interact with numerous other
transcriptional co-activators and repressors. Thus transcription-mediating SMAD complexes can be
highly diverse depending on the activating receptors and depending on the cellular context. This could
lead to ligand-/context-specific gene expression profile explaining the highly diverse TGFβ/BMP ligand
functions observed in vivo.
In summary, the above-listed observations suggest that our astonishment about the conflict
between the highly diverse in vivo functionalities of the TGFβ ligands and a simplistic receptor
mechanism utilizing a far too small set of receptors funneling into just two distinct pathways might be
due to a mis-/overinterpretation of the available data. Considering the above examples, we have to admit
that our current knowledge still lacks too many details about the molecular mechanism of TGFβ/BMP
receptor activation and downstream signaling. While demanding additional novel components to
participate in the ligand-receptor assembly, e.g., co-receptors, could be one route to ensure signal
specification, yet undervalued differences in the intrinsic properties of the various known components,
i.e., differences in the composition of the ligand-receptor assemblies, ligand-receptor affinities, etc.
could also provide with distinct activation states that might be translated into ligand/receptor-specific
gene transcription profiles. Understanding these mechanisms is crucial if we want to design TGFβ/BMP
ligands with tailored functionalities. Such “2nd generation” TGFβ/BMP growth factors are highly
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needed in applications in regenerative medicine and would allow to investigators address defined
functionalities with minimal or no unwanted side effects.
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